Making genuine progress against metastatic breast cancer

J Clin Oncol. 2012 Oct 1;30(28):3448-51. doi: 10.1200/JCO.2012.43.6931. Epub 2012 Aug 27.
No abstract available

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology*
  • Disease-Free Survival
  • Drug Approval
  • Endpoint Determination
  • Female
  • Humans
  • Neoplasm Metastasis
  • Survival Rate
  • United States
  • United States Food and Drug Administration

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab